Age, hormone therapy use, coronary heart disease, and mortality

Menopause

Volumn 18, Issue 3, 2011, Pages 243-245

  Allison, Matthew A ^a   Manson, Joann E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ATHEROSCLEROSIS; CORONARY RISK; DECISION MAKING; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MENOPAUSE; MORTALITY; NONHUMAN; POSTMENOPAUSE; PRIMARY PREVENTION; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WOMEN'S HEALTH;

ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WOMEN'S HEALTH;

EID: 79952191256     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182099c5b     Document Type: Review

References (13)

1. The Women's Health Initiative Steering C. Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701-1712.
2. Writing Group for the Women's Health Initiative I. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-333.
3. Stram DO, Liu Y, Henderson KD, et al. Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause 2011;18: 253-261.
4. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why (Pubitemid 47283647)
5. Grodstein F, Manson J, Colditz G, Willett W, Speizer F, Stampfer M. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133: 933-941. (Pubitemid 32003509)
6. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and risk of coronary heart disease. N Engl J Med 2003;349:523-534. (Pubitemid 36951364)
7. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;116:357-365. (Pubitemid 43244325)
8. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602. (Pubitemid 46961004)
9. Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. J Gen Intern Med 2006;21:363-366.
10. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477. (Pubitemid 46556472)
11. Salpeter SR, Walsh JME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791-804. (Pubitemid 38951954)
12. Grodstein F, Manson J, Stampfer M. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44. (Pubitemid 43192860)
13. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.